Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another Strong Quarter For AbbVie, But How Long Will Good Times Last?

Executive Summary

With continued strong growth for Humira, AbbVie doubles down on confidence to protect the franchise with IP strategy. Imbruvica and Viekira Pak show growth, although the latter is flourishing only ex-US.

Advertisement

Related Content

AbbVie Makes Further Inroads In Oncology As Humira Loss Looms
Nearing Finish Line, HCV Race Focuses On Salvage Therapy
Merck Defends Its Offensive Strategy For Keytruda
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar
Was Rova-T Worth The High Price To AbbVie?
Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch
AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout
AbbVie Banks On “Pipeline In A Molecule” Strategy For Imbruvica

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel